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Objectives: Regorafenib is indicated in the treatment of locally advanced, non-
resectable gastrointestinal stromal tumors (GIST) that did not respond to prior 
imatinib mesylate and sunitinib malate. The objective of this study is to evaluate 
the cost-effectiveness of regorafenib compared to standard care, since no other third 
line treatment is available, in metastatic/inoperable GISTs in Turkey. MethOds: A 
Markov model taking transitions of patients between three health states of “progres-
sion-free”, “progressed” or “dead” was adapted to Turkish settings. Clinical transition 
inputs between health states and safety data were mainly derived from GRID study. 
Economic inputs were based on the experts’ opinion addressing local treatments, 
routine monitoring and adverse event management algorithms. The incremental 
cost-effectiveness ratios (ICER) were calculated per quality adjusted life years (QALY) 
gained. Analyses were conducted from the Turkish Payer Social Security Institution 
perspective. All costs were calculated in Turkish Liras (TL). The cost effectiveness 
(CE) threshold defined by World Health Organization (WHO) for developing countries 
as ICER 1-3 fold of annual income per capita was calculated based on the Turkish 
2014 annual income per capita of 10,404.00 USD and converted to TL using TL/USD 
currency rate of 2.28 (end of 2014). Results: Total costs associated with regorafenib 
and standard care are 22,902 and 1,692 TL, respectively. On the other hand, QALYs 
gained with regorafenib (2.714) was almost twice compared to standard care (1.402), 
with an ICER of 16,481 TL/year. This additional cost of treatment is below the lower 
margin of CE threshold that was 23,721.00 TL. cOnclusiOns: Regorafenib is a cost-
effective treatment option in metastatic/inoperable GISTs in Turkey. Compared to 
standard care, the additional cost of treatment is below the CE threshold.
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Objectives: Sunitinib is a multitargeted receptor tyrosine kinase inhibitor that has 
demonstrated its efficacy in treating Gastrointestinal stromal tumor (GIST) patients 
who are no longer responded to imatinib 400mg/day. The purpose of this study is to 
evaluate the cost-effectiveness of sunitinib as a second-line treatment in patients 
with advanced GISTs in China from a third party payer’s perspective. MethOds: 
A Markov model was developed to simulate disease progression and to determine 
cost and effectiveness outcomes over a 5-year time horizon. The different second-
line treatment arms compared were sunitinib 50 mg/day (4 weeks on and 2 weeks 
off), imatinib 600 mg/day, imatinib 800 mg/day, and best supportive care (BSC). The 
probabilities of state transitions and utilities were obtained from previous published 
trials. Resource use and costs data were obtained from previous studies and public 
sources. A 3.5% annual discount rate after the first year was applied to both costs 
and outcomes. The incremental cost-effectiveness ratios (ICER) between treatment 
with sunitinib vs. other treatment options were calculated. Results: In the base 
case, treatment with sunitinib vs. imatinib 600 mg resulted in 0.744 PFLY gained, 
0.423 LY gained and 0.398 QALYs gained at an incremental cost of RMB14,750. The 
ICER was RMB37,023 per QALY gained. Treatment with sunitinib was dominant 
compared with imatinib 800 mg, with lower costs and higher QALYs . Treatment 
with sunitinib vs BSC resulted in patients’ benefits of 0.257 PFLY gained, 1.357 LY 
gained and 0.836 QALYs gained at an incremental cost of RMB106,889. The ICER 
was RMB127,801 per QALY gained. cOnclusiOns: Among patients with advanced 
GISTs who have failed imatinib 400mg/day as the first-line treatment, sunitinib 
provides greater clinical benefit than high-dose imatinib or BSC. In the Chinese 
setting, sunitinib is estimated to be either cost-saving or cost-effective compared 
with imatinib 800 mg, imatinib 600mg or BSC.
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Objectives: To assess the cost-effectiveness of ceritinib versus other therapies in 
the treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung 
cancer (NSCLC) from the UK National Health Service (NHS) and Personal Social 
Service (PSS) perspective. MethOds: A partitioned survival model with three health 
states (progression-free, progressive, and death) was developed to compare ceri-
tinib versus other treatments in patients with ALK+ NSCLC who were previously 
treated with chemotherapy (post-CT), or with an ALK inhibitor, regardless of prior 
chemotherapy (post-ALKi). The comparator arms included crizotinib, docetaxel, and 
pemetrexed in the post-CT population and best supportive care (BSC), docetaxel, 
and pemetrexed in the post-ALKi population. Progression-free survival and overall 
survival for ceritinib were estimated using the ASCEND-1 (NCT01283516), ASCEND-2 
(NCT01685060), and ASCEND-3 (NCT01685138) trial data. Parametric models were 
used to extrapolate outcomes beyond the trial period. Survival data for compara-
tors were obtained from published clinical trials. Drug acquisition, administration, 
medical and adverse event (AE) costs were obtained from publicly available data-
bases. Utilities for health states and disutilities for AEs based on EQ-5D were derived 
from literature. Incremental costs per quality-adjusted life year (QALY) gained were 
estimated comparing ceritinib vs. each comparator. Univariate and probabilistic 
sensitivity analyses were performed. Results: Over 10 years, ceritinib was associ-
ated with 2.69 QALYs and total direct costs of £80,445 for post-CT population. The 
incremental cost per QALY was £30,536 comparing ceritinib vs. crizotinib, £44,847 vs. 
docetaxel, and £38,966 vs. pemetrexed. Among post-ALKi population, the QALY and 
total direct costs for ceritinib were 0.94 and £45,712 respectively. The incremental 
cost per QALY was £48,808 comparing ceritinib vs. BSC, £57,660 vs. docetaxel, and 
£40,145 vs. pemetrexed. Sensitivity analysis results were consistent with the base-
case findings. cOnclusiOns: Based on the willingness-to-pay threshold for end-
(iii) best supportive care (BSC). To compare I+R to steroids with rituximab (an 
alternative treatment for the patient group in Study 116) and to make exploratory 
comparisons to chemo-immunotherapies, curve fits to systematically-identified 
comparator trial data were made using a common-shape approach and adjust-
ment for prognostic factors. Utility data and drug, medical resource, adverse event 
and terminal care costs were obtained from Study 116 EQ-5D surveys, published 
sources and clinical input. Results: Compared to (i) rituximab monotherapy, (ii) 
ofatumumab monotherapy and (iii) BSC, in patients ineligible for chemo-immu-
notherapy, the base case ICERs for I+R were (i) £21,224, (ii) £9,116 and (iii) £28,015 
per QALY gained, respectively and inclusive of a simple price discount. Further 
comparisons provided ICERs ranging from £20,431 to £34,603. cOnclusiOns: 
I+R was shown to be cost effective in previously-treated patients ineligible for 
chemo-immunotherapy.
PCN142
Cost-EffECtivENEss of ofAtumumAb PLus ChLorAmbuCiL iN first-LiNE 
ChroNiC LymPhoCytiC LEuKEmiA iN thE uNitEd KiNGdom
Pearson IV1, Hawe E1, Zuluaga S1, Wolowacz S1, Haiderali A2
1RTI Health Solutions, Manchester, UK, 2Merck, North Wales, PA, USA
Objectives: To evaluate the cost-effectiveness of ofatumumab plus chlorambucil 
(OChl) versus chlorambucil (Chl) for the first-line treatment of chronic lympho-
cytic leukemia (CLL) in patients not eligible for fludarabine-based therapy from the 
United Kingdom health care payer perspective. MethOds: A semi-Markov decision 
model was developed with a lifetime time horizon of 25 years and a 3-month cycle 
length. The COMPLEMENT-1 trial provided estimates of overall response rates (ORR), 
progression-free survival (PFS), overall survival (OS), safety data, and preprogression 
utility weights (EQ-5D). The number of patients in the “preprogression,” “progres-
sive disease,” and “dead” health states at the end of each cycle was determined by 
parametric survival functions for PFS and OS. Long-term predictions for OS were 
guided by external data; the treatment effect observed in the trial was assumed not 
to continue beyond trial follow-up. Data from published literature and UK treatment 
practices and patterns were used to inform costs and utility in the postprogression 
health states. Incremental lifetime costs and quality-adjusted life-years (QALYs) 
were calculated. Results: The base-case incremental cost-effectiveness ratio (ICER) 
was £32,950 per QALY gained, with incremental discounted costs and QALYs of 
£10,492 and 0.32, respectively. Discount rate was 3.5% for both cost and outcomes. 
The probability of cost-effectiveness at a willingness-to-pay threshold of £30,000 
per QALY was 43%. Univariate sensitivity analyses indicated that the proportion of 
patients who received active therapy after progression following first-line treatment 
(responders, active second-line treatment) had the largest influence on the ICER. 
However, none of the variables considered generated an ICER exceeding £38,000 
per QALY gained. cOnclusiOns: The improved ORR, PFS, and OS for OChl com-
pared with Chl translated to improved long-term health outcomes in the base-case 
analysis. The results were robust in a wide range of sensitivity analyses and did not 
exceed £38,000/QALY.
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Objectives: Idelalisib/ rituximab (IR) is licenced for the treatment of adults 
with CLL who either have received at least one previous therapy and as first 
line treatment for patients with del17p/TP53 mutations. Prior to the availability 
of IR, individuals in these patient groups received best supportive care (BSC). 
The clinical efficacy of the IR in these patient groups was demonstrated in a 
Phase III RCT (‘study 116’). The cost-effectiveness of IR in this patient group is 
unknown. MethOds: A response stratified partitioned survival model (overall 
survival - OS, progression free survival - PFS) was developed to estimate the life-
time costs and benefits associated with IR and BSC for a Scottish NHS perspective 
using a lifetime horizon and monthly cycles. OS, PFS, overall response (OR) and 
resource use data was taken directly from study 116. Information from study 
116 was used as far as possible for patients with del17p / TP53 mutations, with 
expert opinion used where necessary. Utility scores were taken from published 
sources. Unit/drug costs were taken from national databases and discounted at 
3.5% p.a. Probabilistic and deterministic sensitivity analyses were conducted to 
estimate the confidence around the results. Outcomes are reported via incremen-
tal cost-effectiveness ratios (ICER, benefit expressed as QALYs). Results: For all 
patients the ICER for all patients was £32,180/ QALY (Δ QALYs:2.04, Δ Costs:£64,629). 
In patients with del 17p/TP53 mutations the ICER was £19,040/QALY (Δ QALYs:4.39, 
Δ Costs:£83,636). The results were sensitive to changes in OR rates and utility val-
ues. In particular, the ICERs fell below £30,000/QALY if utility values from previ-
ous UK HTAs of treatments for CLL were used. The ICERs were robust to changes 
in adverse event rates/costs and alterations to background resource use pat-
terns. cOnclusiOns: IR is likely to be a cost-effective intervention in all CLL 
patients for which it has achieved European marketing approval.
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